Nektar Therapeutics
NKTR58.760USD
+7.690+15.06%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
731.99MValor de mercado
PerdaP/L TTM
Mais detalhes de Nektar Therapeutics Empresa
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Informações da empresa
Código da empresaNKTR
Nome da EmpresaNektar Therapeutics
Data de listagemMay 03, 1994
CEOMr. Howard W. Robin
Número de funcionários61
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 03
Endereço455 Mission Bay Boulevard South
CidadeSAN FRANCISCO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94158
Telefone18554826587
Sitehttps://www.nektar.com/
Código da empresaNKTR
Data de listagemMay 03, 1994
CEOMr. Howard W. Robin
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 10 de set
Atualizado em: qua, 10 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
Outro
80.06%
Investidores
Investidores
Proporção
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
Outro
80.06%
Tipos de investidores
Investidores
Proporção
Hedge Fund
22.42%
Investment Advisor
14.24%
Investment Advisor/Hedge Fund
9.72%
Research Firm
1.82%
Individual Investor
0.71%
Family Office
0.23%
Venture Capital
0.08%
Pension Fund
0.01%
Outro
50.76%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
2023Q1
545
178.73M
94.47%
-35.40M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
820.65K
4.92%
-1.22K
-0.15%
Mar 31, 2025
Nantahala Capital Management, LLC
519.27K
3.12%
-1.40K
-0.27%
Mar 31, 2025
Millennium Management LLC
932.86K
5.6%
+780.28K
+511.36%
Jun 27, 2025
AQR Capital Management, LLC
242.72K
1.46%
+187.17K
+336.95%
Mar 31, 2025
Acadian Asset Management LLC
486.78K
2.92%
+6.71K
+1.40%
Mar 31, 2025
PRIMECAP Management Company
356.97K
2.14%
-12.39K
-3.35%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
873.88K
5.24%
-15.04K
-1.69%
Mar 31, 2025
TCG Crossover Management, LLC
266.67K
1.6%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de set
Atualizado em: ter, 2 de set
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.9%
Simplify Health Care ETF
0.84%
Fidelity Enhanced Small Cap ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Schwab U.S. Small-Cap ETF
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.9%
Simplify Health Care ETF
Proporção0.84%
Fidelity Enhanced Small Cap ETF
Proporção0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.03%
Schwab U.S. Small-Cap ETF
Proporção0.01%
iShares Biotechnology ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
ProShares Ultra Nasdaq Biotechnology
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
